A Rofecoxib‐Derived Theranostic Probe and Its Combination With PD‐1 Inhibitor for High‐Efficiency Cancer Therapy
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Xinli Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China. Hauptthemen laut MEDLINE: Lactones, Cyclooxygenase 2 Inhibitors, Sulfones, Immune Checkpoint Inhibitors. Die Arbeit nennt 36 Literaturangaben. Gefördert von: This study was supported by Joint Funds for the Innovation of Science and Technology, Fujian Province (2023Y9166)..
Abstract (Originalsprache)
The development of theranostic probes with tumor‐specific targeting and high therapeutic efficacy remains a pivotal challenge in precision oncology. Herein, we have successfully developed a new cyclooxygenase‐2 (COX‐2)‐targeted probe compound 2 derived from Rofecoxib. Compound 2 facilitated tumor visualization by a sixfold fluorescence enhancement upon COX‐2 binding, while it exhibited minimal background fluorescence under physiological conditions. Moreover, compound 2 monotherapy achieved 53% tumor regression ( p < 0.01). When combined with a programmed cell death protein 1 (PD‐1) inhibitor (RMP1‐14), concurrent blockade of the COX‐2/prostaglandin E2 (PGE2) and PD‐1/programmed death‐ligand 1 (PD‐L1) axes achieved 95% tumor regression ( p < 0.001). Compound 2 involves activating fluorescence by targeting tumor markers COX‐2 as well as enhancing therapeutic efficacy. We believe this approach could provide insights for advancing cancer diagnosis and treatment technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
- Fujian Provincial Key Laboratory of Screening for Novel Microbial Products, Fujian Institute of Microbiology, Fuzhou, Fujian, People's Republic of China.
- College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian, People's Republic of China.
ORCID-Profile: Lijun Xie
Förderung
- This study was supported by Joint Funds for the Innovation of Science and Technology, Fujian Province (2023Y9166).
Zitieren
APA
Wang, X., Wang, X., Su, X., Wang, Z., Sun, Y., Xie, L., & Lin, X. (2025). A Rofecoxib‐Derived Theranostic Probe and Its Combination With PD‐1 Inhibitor for High‐Efficiency Cancer Therapy. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70155
Vancouver
Wang X, Wang X, Su X, Wang Z, Sun Y, Xie L, et al. A Rofecoxib‐Derived Theranostic Probe and Its Combination With PD‐1 Inhibitor for High‐Efficiency Cancer Therapy. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70155
BibTeX
@article{Wang2025,
author = {Wang, Xinli and Wang, Xia and Su, Xuejing and Wang, Zexin and Sun, Yongxiao and Xie, Lijun and Lin, Xiaoyan},
title = {A Rofecoxib‐Derived Theranostic Probe and Its Combination With PD‐1 Inhibitor for High‐Efficiency Cancer Therapy},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70155}
}
EUVIMED